Ketoconazole/ˌkiːtɵˈkoʊnəzɒl/ is a synthetic, imidazole-derived antifungal medication used primarily to treat fungal infections. Ketoconazole is sold commercially as a tablet for oral administration, and in a variety of formulations, such as creams and shampoos, for topical administration.
The less toxic and generally more effective triazole antifungal agents fluconazole and itraconazole are usually preferred for internal use. The European Medicines Agency's Committee on Medicinal Products for Human Use (CHMP) has recommended that a ban be imposed on the use of ketoconazole for systemic use in humans throughout the European Union, after concluding that the risk of serious liver injury from systemic ketoconazole outweights its benefits.
Ketoconazole has activity against many kinds of fungi that may cause human disease, such as Candida, Histoplasma, Coccidioides, and Blastomyces (although it is not active against Aspergillus). First synthesized in 1977, ketoconazole was the first orally active azole antifungal medication. However, ketoconazole has largely been replaced as a first-line systemic antifungal medication by other azole antifungal agents, such as itraconazole, because of ketoconazole's greater toxicity, poorer absorption, and more limited spectrum of activity.
Antiandrogenic and antiglucocorticoid[edit source | edit]
The side effects of ketoconazole are sometimes harnessed in the treatment of nonfungal conditions. While ketoconazole blocks the synthesis of the plant sterol ergosterol in fungi, in human beings it inhibits the activity of several enzymes necessary for the conversion of cholesterol to steroid hormones such as testosterone and cortisol. Based on these antiandrogen and antiglucocorticoid effects, ketoconazole has been used as a second-line treatment for certain forms of advanced prostate cancer and for the suppression of glucocorticoid synthesis in the treatment of Cushing's syndrome.
Veterinary[edit source | edit]
This medication is also sometimes prescribed by veterinarians for use on pets, often as unflavored tablets that may need to be cut to smaller size for correct dosage.
As an antiandrogen, ketoconazole operates through at least two mechanisms of action. First, and most notably, high oral doses of ketoconazole (e.g. 400 mg three times per day) block both testicular and adrenal androgen biosynthesis, leading to a reduction in circulating testosterone levels. It produces this effect through inhibition of cytochrome P450 isozyme 3A4 and 17,20-lyase, which are involved in the synthesis and degradation of steroids, including the precursors of testosterone. Due to its efficacy at reducing systemic androgen levels, ketoconazole has been used as a treatment for androgen-dependent prostate cancer. Second, ketoconazole is an androgen receptorantagonist, competing with androgens such as testosterone and DHT for androgen receptor binding. This effect is thought to be quite weak, even with high oral doses of ketoconazole.
Administration & absorption[edit source | edit]
When administered orally, ketoconazole is best absorbed at highly acidic levels, so antacids or other causes of decreased stomach acid levels will lower the drug's absorption. Absorption can be increased by taking it with an acidic beverage, such as cola. Ketoconazole is very lipophilic and tends to accumulate in fatty tissues.
Resistance to ketoconazole has been observed in a number of clinical fungal isolates, including Candida albicans. Experimentally, resistance usually arises as a result of mutations in the sterol biosynthesis pathway. Defects in the sterol 5-6 desaturase enzyme reduce the toxic effects of azole inhibition of the 14-alpha demethylation step. Multidrug-resistance (MDR) genes can also play a role in reducing cellular levels of the drug. As azole antifungals all act at the same point in the sterol pathway, resistant isolates are normally cross-resistant to all members of the azole family.
Off label uses[edit source | edit]
Hair loss[edit source | edit]
Nizoral (ketoconazole) 2% shampoo
Ketoconazole shampoo in conjunction with systemic antiandrogens treatment has been used off label to treat androgenic alopecia. Its anti-fungal properties reduce scalp microflora and consequently may reduce follicular inflammation that contributes to alopecia. Furthermore ketoconazole blocks the local synthesis of DHT in the scalp as well as acts as a antagonist of the androgen receptor. Hence it has been hypothesized that ketoconazole when used together with systemic antiandrogens may result in a more complete blockade of androgen receptor in the scalp and consequently may lead to a more effective treatment of androgenic alopecia.
Limited clinical studies suggest that ketoconazole shampoo used either alone or in combination with other treatments may be useful in reducing hair loss.
Adverse effects[edit source | edit]
This section requires expansion. (May 2013)
It is a pregnancy category C drug because animal testing has shown it to cause teratogenesis when administered in high doses. Recently, the administration of systemic ketoconazole to two pregnant women for treatment of Cushing's syndrome was reported to have no adverse effects, but this small sample precludes drawing any meaningful conclusions. A subsequent trial in Europe failed to show a risk to infants of mothers receiving ketoconazole.
Synthesis[edit source | edit]
The first racemic synthesis of ketoconazole was published in 1979. In this synthesis, cis- and trans-isomers were separated by crystallization because only the two cis-enantiomers are used in the commercially available drug.
Synthesis of ketoconazole (8)
The synthesis was started with dichloroacetophenone (1) and glycerine. The ketal was directly brominated to yield alcohol 2. This was further transformed into the corresponding benoylic ester 3 and at this stage cis- and trans-isomers were separated. The imidazole residue was then introduced followed by a basic hydrolysis of the ester moiety. The free hydroxyl group of 5 was converted into the mesylate and was then replaced by substituent 7 to yield ketoconazole 8 in six steps and an overall yield of 12%.
^ abcPhillips RM, Rosen T (2013). "Topical Antifungal Agents". In Wolverton SE. Comprehensive Dermatologic Therapy (3rd ed.). Philadelphia: Saunders. pp. 460–472. ISBN978-1-4377-2003-7.
^Neider R, Fritsch PO (2012). "Other Eczematous Eruptions". In Bolognia JL. Dermatology (3rd ed.). Philadelphia: Saunders. pp. 219–221. ISBN9780723435716.
^Young BK, Brodell RT, Cooper KD (2013). "Therapeutic Shampoos". In Wolverton SE. Comprehensive Dermatologic Therapy (3rd ed.). Philadelphia: Saunders. pp. 562–569. ISBN978-1-4377-2003-7.
^ abcdFinkel R, Cubeddu LX, Clark MA (2009). Pharmacology (4th ed.). Baltimore: Lippincott Williams & Wilkins. p. 411.
^Kauffman CA (2004). "Introduction to the Mycoses". In Goldman L, Ausiello, D. Cecil Textbook of Medicine (22nd ed.). Philadelphia: Saunders. p. 2043. ISBN0-7216-9652-X.
^Zelefsky MJ, Eastham JA, Sartor OA, Kantoff P (2008). DeVita VT, Lawrence TS, Rosenberg SA, ed. Cancer: Principles & Practice of Oncology (8th ed.). Philadelphia: Lippincott Williams & Wilkins. p. 1443. ISBN9780781772075.
^Loli P, Berselli ME, Tagliaferri M (December 1986). "Use of ketoconazole in the treatment of Cushing's syndrome". J. Clin. Endocrinol. Metab.63 (6): 1365–71. doi:10.1210/jcem-63-6-1365. PMID3023421.
^Piérard-Franchimont C, De Doncker P, Cauwenbergh G, Piérard GE (1998). "Ketoconazole shampoo: effect of long-term use in androgenic alopecia". Dermatology (Basel)196 (4): 474–7. doi:10.1159/000017954. PMID9669136.
^Piérard-Franchimont C, Goffin V, Henry F, Uhoda I, Braham C, Piérard GE (October 2002). "Nudging hair shedding by antidandruff shampoos. A comparison of 1% ketoconazole, 1% piroctone olamine and 1% zinc pyrithione formulations". Int J Cosmet Sci24 (5): 249–56. doi:10.1046/j.1467-2494.2002.00145.x. PMID18498517.
^Khandpur S, Suman M, Reddy BS (August 2002). "Comparative efficacy of various treatment regimens for androgenetic alopecia in men". J. Dermatol.29 (8): 489–98. PMID12227482.
^Berwaerts J, Verhelst J, Mahler C, Abs R (June 1999). "Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature". Gynecol. Endocrinol.13 (3): 175–82. doi:10.3109/09513599909167552. PMID10451809.
^ abHeeres J, Backx LJ, Mostmans JH, Van Cutsem J (August 1979). "Antimycotic imidazoles. part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent". J. Med. Chem.22 (8): 1003–5. doi:10.1021/jm00194a023. PMID490531.